<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font26 { font-size : 26; } .font28 { font-size : 28; } .font29 { font-size : 29; } .font30 { font-size : 30; } .font31 { font-size : 31; }</style>
 <body>
  <p>
   <span class="font31">[]. </span>
   <span class="font30">feline </span>
   <span class="font29">virus </span>
   <span class="font28">cats </span>
   <span class="font26">FIV </span>
   <span class="font26">immunodeficiency </span>
   <span class="font26">treatment </span>
   <span class="font20">FIV-infected </span>
   <span class="font19">antiviral </span>
   <span class="font19">yes </span>
   <span class="font18">studies </span>
   <span class="font17">HIV </span>
   <span class="font17">clinical </span>
   <span class="font17">vitro </span>
   <span class="font17">[,]. </span>
   <span class="font17">active </span>
   <span class="font17">viral </span>
   <span class="font16">infection </span>
   <span class="font16">replication </span>
   <span class="font16">effects </span>
   <span class="font16">reverse </span>
   <span class="font16">{border-style </span>
   <span class="font16">human </span>
   <span class="font16">used </span>
   <span class="font15">px;} </span>
   <span class="font15">#ffffff;} </span>
   <span class="font15">DNA </span>
   <span class="font15">effect </span>
   <span class="font15">transcriptase </span>
   <span class="font14">efficacy </span>
   <span class="font14">oral </span>
   <span class="font14">vivo </span>
   <span class="font14">cats. </span>
   <span class="font14">drug </span>
   <span class="font14">inhibitors </span>
   <span class="font14">nucleoside </span>
   <span class="font14">Vet. </span>
   <span class="font14">compounds </span>
   <span class="font14">effective </span>
   <span class="font14">naturally </span>
   <span class="font13">Inhibitors </span>
   <span class="font13">activity </span>
   <span class="font13">cell </span>
   <span class="font13">infected </span>
   <span class="font13">likely </span>
   <span class="font13">drugs </span>
   <span class="font13">shown </span>
   <span class="font13">toxic </span>
   <span class="font13">treated </span>
   <span class="font13">zidovudine </span>
   <span class="font13">U/kg </span>
   <span class="font13">approved </span>
   <span class="font13">including </span>
   <span class="font13">ribavirin </span>
   <span class="font13">secondary </span>
   <span class="font12">Feline </span>
   <span class="font12">administration </span>
   <span class="font12">anti-HIV </span>
   <span class="font12">consecutive </span>
   <span class="font12">improvement </span>
   <span class="font12">proviral </span>
   <span class="font12">rFeIFN-ω </span>
   <span class="font12">site </span>
   <span class="font12">study </span>
   <span class="font12">therapy </span>
   <span class="font12">type </span>
   <span class="font12">available </span>
   <span class="font12">cells </span>
   <span class="font12">days </span>
   <span class="font12">effective, </span>
   <span class="font12">enzyme </span>
   <span class="font12">group </span>
   <span class="font12">inhibitor </span>
   <span class="font12">interferon </span>
   <span class="font12">leukemia </span>
   <span class="font12">potent </span>
   <span class="font12">px; </span>
   <span class="font12">use </span>
   <span class="font12">{font-family </span>
   <span class="font12">Agents </span>
   <span class="font12">FIV, </span>
   <span class="font12">RNA </span>
   <span class="font12">Suramin </span>
   <span class="font12">Virol. </span>
   <span class="font12">bind </span>
   <span class="font12">cats, </span>
   <span class="font12">different </span>
   <span class="font12">dose </span>
   <span class="font12">experimental </span>
   <span class="font12">font-size </span>
   <span class="font12">inhibit </span>
   <span class="font12">inhibits </span>
   <span class="font12">possibly </span>
   <span class="font12">resistance </span>
   <span class="font12">results </span>
   <span class="font12">selective </span>
   <span class="font12">viruses </span>
   <span class="font11">(e.g., </span>
   <span class="font11">.De </span>
   <span class="font11">Adefovir </span>
   <span class="font11">EBM </span>
   <span class="font11">HIV- </span>
   <span class="font11">However, </span>
   <span class="font11">Pharmacol. </span>
   <span class="font11">Thus, </span>
   <span class="font11">Transcriptase </span>
   <span class="font11">[,,]. </span>
   <span class="font11">binding </span>
   <span class="font11">chain </span>
   <span class="font11">data </span>
   <span class="font11">did </span>
   <span class="font11">double; </span>
   <span class="font11">gene </span>
   <span class="font11">high </span>
   <span class="font11">immune </span>
   <span class="font11">inhibition </span>
   <span class="font11">nucleotide </span>
   <span class="font11">protease </span>
   <span class="font11">resistant </span>
   <span class="font11">severe </span>
   <span class="font11">study, </span>
   <span class="font11">virus-infected </span>
   <span class="font11">vitro, </span>
   <span class="font11">CXCR </span>
   <span class="font11">Foscarnet </span>
   <span class="font11">Human </span>
   <span class="font11">IFN-α </span>
   <span class="font11">IFNs </span>
   <span class="font11">Immunol. </span>
   <span class="font11">Med. </span>
   <span class="font11">Nucleotide </span>
   <span class="font11">Res../ </span>
   <span class="font11">Reverse </span>
   <span class="font11">Ribavirin </span>
   <span class="font11">U/cat </span>
   <span class="font11">adefovir </span>
   <span class="font11">administered </span>
   <span class="font11">anti-FIV </span>
   <span class="font11">antiretroviral </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">cellular </span>
   <span class="font11">chemokine </span>
   <span class="font11">combination </span>
   <span class="font11">common </span>
   <span class="font11">effects, </span>
   <span class="font11">field </span>
   <span class="font11">ineffective </span>
   <span class="font11">infections </span>
   <span class="font11">integrase </span>
   <span class="font11">intracellular </span>
   <span class="font11">lamivudine </span>
   <span class="font11">licensed </span>
   <span class="font11">mutation </span>
   <span class="font11">natural </span>
   <span class="font11">new </span>
   <span class="font11">non-nucleoside </span>
   <span class="font11">phosphate </span>
   <span class="font11">plerixafor </span>
   <span class="font11">receptor </span>
   <span class="font11">recombinant </span>
   <span class="font11">retroviral </span>
   <span class="font11">solid; </span>
   <span class="font11">synthesis </span>
   <span class="font11">toxicity </span>
   <span class="font11">veterinary </span>
   <span class="font11">years </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font11">(most </span>
   <span class="font11">Abacavir </span>
   <span class="font11">Acad. </span>
   <span class="font11">Chemother../AAC... </span>
   <span class="font11">Didanosine </span>
   <span class="font11">Interferons </span>
   <span class="font11">Intern. </span>
   <span class="font11">Lamivudine </span>
   <span class="font11">NARTIs </span>
   <span class="font11">NNRTIs </span>
   <span class="font11">Natl. </span>
   <span class="font11">Plerixafor </span>
   <span class="font11">Res. </span>
   <span class="font11">Sci. </span>
   <span class="font11">Stavudine </span>
   <span class="font11">Tenofovir </span>
   <span class="font11">USA./pnas... </span>
   <span class="font11">Zidovudine </span>
   <span class="font11">[,], </span>
   <span class="font11">acid </span>
   <span class="font11">acid, </span>
   <span class="font11">acyclic </span>
   <span class="font11">addition, </span>
   <span class="font11">agents </span>
   <span class="font11">alternative </span>
   <span class="font11">article </span>
   <span class="font11">associated </span>
   <span class="font11">blood </span>
   <span class="font11">bold </span>
   <span class="font11">compound. </span>
   <span class="font11">controlled </span>
   <span class="font11">courier; </span>
   <span class="font11">days) </span>
   <span class="font11">decrease </span>
   <span class="font11">development </span>
   <span class="font11">double-blinded </span>
   <span class="font11">em; </span>
   <span class="font11">experimentally </span>
   <span class="font11">foscarnet </span>
   <span class="font11">grade </span>
   <span class="font11">humans </span>
   <span class="font11">infection) </span>
   <span class="font11">interfere </span>
   <span class="font11">long </span>
   <span class="font11">low </span>
   <span class="font11">major </span>
   <span class="font11">marked </span>
   <span class="font11">necessary </span>
   <span class="font11">parenteral </span>
   <span class="font11">placebo </span>
   <span class="font11">placebo-controlled </span>
   <span class="font11">placebo-controlled, </span>
   <span class="font11">potential </span>
   <span class="font11">potentially </span>
   <span class="font11">prevent </span>
   <span class="font11">produced </span>
   <span class="font11">pt;} </span>
   <span class="font11">raltegravir </span>
   <span class="font11">recent </span>
   <span class="font11">receptors </span>
   <span class="font11">response </span>
   <span class="font11">retrovirus </span>
   <span class="font11">retroviruses </span>
   <span class="font11">review </span>
   <span class="font11">showed </span>
   <span class="font11">significant </span>
   <span class="font11">signs </span>
   <span class="font11">similar </span>
   <span class="font11">target </span>
   <span class="font11">various </span>
  </p>
 </body>
</html>
